Endocannabinoid transport revisited

Vitamins and Hormones

Volumn 98, Issue , 2015, Pages 441-485

  Nicolussi, Simon ^a   Gertsch, Jürg ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; N-ARACHIDONOYLETHANOLAMINE;

ANIMAL; CELL MEMBRANE; HUMAN; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; ENDOCANNABINOIDS; HUMANS;

EID: 84955635304     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.vh.2014.12.011     Document Type: Chapter

References (154)

1. Alexander, J. P., & Cravatt, B. F. (2006). The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society, 128, 9699-9704.
2. Bab, I., Ofek, O., Tam, J., Rehnelt, J., & Zimmer, A. (2008). Endocannabinoids and the regulation of bone metabolism. Journal of Neuroendocrinology, 20(Suppl. 1), 69-74.
3. Bari, M., Paradisi, A., Pasquariello, N., & Maccarrone, M. (2005). Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. Journal of Neuroscience Research, 81, 275-283.
4. Basavarajappa, B. (2007). Critical enzymes involved in endocannabinoid metabolism. Protein and Peptide Letters, 14, 237-246.
5. Batista, L. A., Gobira, P. H., Viana, T. G., Aguiar, D. C., & Moreira, F. A. (2014). Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behavioural Pharmacology, 25, 425-433.
6. Baur, R., Gertsch, J., & Sigel, E. (2013). Do N-arachidonyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the β2 subunit of GABAA receptors? PeerJ, 1, e149.
7. Beltramo, M., & Piomelli, D. (1999). Anandamide transport inhibition by the vanilloid agonist olvanil. European Journal of Pharmacology, 364, 75-78.
8. Beltramo, M., & Piomelli, D. (2000). Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport, 11, 1231-1235.
9. Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
10. Berger, W. T., Ralph, B. P., Kaczocha, M., Sun, J., Balius, T. E., Rizzo, R. C., et al. (2012). Targeting fatty acid binding protein (FABP) anandamide transporters-A novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One, 7, e50968.
11. Bernabò, N., Barboni, B., & Maccarrone, M. (2013). Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol. Omics: A Journal of Integrative Biology, 17, 646-654.
12. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., et al. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. The Journal of Cell Biology, 163, 463-468.
13. Bisogno, T., Maccarrone, M., De Petrocellis, L., Jarrahian, A., Finazzi-Agrò , A., Hillard, C., et al. (2001). The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. European Journal of Biochemistry, 268, 1982-1999.
14. Bisogno, T., Melck, D., Bobrov, M., Gretskaya, N. M., Bezuglov, V., De Petrocellis, L., et al. (2000). N-acyl-dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. The Biochemical Journal, 351, 817-824.
15. Björklund, E., Larsson, T. N. L., Jacobsson, S. O. P., & Fowler, C. J. (2014). Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. PLoS One, 9, e87542.
16. Blankman, J. L., & Cravatt, B. F. (2013). Chemical probes of endocannabinoid metabolism. Pharmacological Reviews, 65, 849-871.
17. Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology, 14, 1347-1356.
18. Brown, A. J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology, 152, 567-575.
19. Brown, D. A., & London, E. (2000). Structure and function of sphingolipid-and cholesterolrich membrane rafts. The Journal of Biological Chemistry, 275, 17221-17224.
20. Buczynski, M. W., & Parsons, L. H. (2010). Quantification of brain endocannabinoid levels: Methods, interpretations and pitfalls. British Journal of Pharmacology, 160, 423-442.
21. Burch, P., Chicca, A., Gertsch, J., & Gademann, K. (2014). Functionally optimized neuritogenic farinosone C analogs: SAR-study and investigations on their mode of action. ACS Medicinal Chemistry Letters, 5, 172-177.
22. Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012). Endocannabinoid signaling and synaptic function. Neuron, 76, 70-81.
23. Chicca, A., Caprioglio, D., Minassi, A., Petrucci, V., Appendino, G., Taglialatela-Scafati, O., et al. (2014). Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. ACS Chemical Biology, 9, 1499-1507.
24. Chicca, A., Marazzi, J., Nicolussi, S., & Gertsch, J. (2012). Evidence for bidirectional endocannabinoid transport across cell membranes. The Journal of Biological Chemistry, 287, 34660-34682.
25. Cravatt, B., Giang, D., & Mayfield, S. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384, 83-87.
26. Day, T., Rakhshan, F., Deutsch, D. G., & Barker, E. L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Molecular Pharmacology, 59, 1369-1375.
27. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters, 483, 52-56.
28. Deutsch, D. G., & Chin, S. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochemical Pharmacology, 46, 791-796.
29. Deutsch, D. G., Glaser, S. T., Howell, J. M., Kunz, J. S., Puffenbarger, R., Hillard, C. J., et al. (2001). The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. The Journal of Biological Chemistry, 276, 6967-6973.
30. Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
31. Di, S., Boudaba, C., Popescu, I. R., Weng, F. J., Harris, C., Marcheselli, V. L., et al. (2005). Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. The Journal of Physiology, 569, 751-760.
32. Dickason-Chesterfield, A. K., Kidd, S. R., Moore, S. A., Schaus, J. M., Liu, B., Nomikos, G. G., et al. (2006). Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cellular and Molecular Neurobiology, 26, 407-423.
33. Di Marzo, V. (2006). Endocannabinoids: Synthesis and degradation. Reviews of Physiology, Biochemistry and Pharmacology, 160, 1-24.
34. Di Marzo, V. (2008). Targeting the endocannabinoid system: To enhance or reduce? Nature Reviews Drug Discovery, 7, 438-455.
35. Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 3, 771-784.
36. Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., et al. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry, 264, 258-267.
37. Di Marzo, V., Bisogno, T., Suguira, T., Melck, D., & De Petrocellis, L. (1998). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal-and basophil-like cells: Connections with anandamide. Biochemical Journal, 331, 15-19.
38. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J., et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
39. Di Marzo, V., Ligresti, A., Morera, E., Nalli, M., & Ortar, G. (2004). The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorganic & Medicinal Chemistry, 12, 5161-5169.
40. Dinh, T. P., Kathuria, S., & Piomelli, D. (2004). RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Molecular Pharmacology, 66, 1260-1264.
41. Di Pasquale, E., Chahinian, H., Sanchez, P., & Fantini, J. (2009). The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent. PLoS One, 4, e4989.
42. Fasia, L., Karava, V., & Siafaka-Kapadai, A. (2003). Uptake and metabolism of [3H]anandamide by rabbit platelets. Lack of transporter? European Journal of Biochemistry, 270, 3498-3506.
43. Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., et al. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America, 101, 8756-8761.
44. Felder, C. C., Dickason-Chesterfield, A. K., & Moore, S. A. (2006). Cannabinoid biology. Molecular Interventions, 6, 149-161.
45. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., & Di, V. (2002). Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Letters, 513, 294-298.
46. Fowler, C. J. (2012). Anandamide uptake explained? Trends in Pharmacological Sciences, 33, 181-185.
47. Fowler, C. J. (2013). Transport of endocannabinoids across the plasma membrane and within the cell. The FEBS Journal, 280, 1895-1904.
48. Fowler, C. J. (2014). Has FLAT fallen flat? Trends in Pharmacological Sciences, 35, 51-52.
49. Fowler, C. J., & Ghafouri, N. (2008). Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 58, 72-76.
50. Fowler, C. J., Tiger, G., Ligresti, A., López-Rodríguez, M. L., &Di Marzo, V. (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis-A difficult issue to handle. European Journal of Pharmacology, 492, 1-11.
51. Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., et al. (2011). A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience, 15, 64-69.
52. Furuhashi, M., & Hotamisligil, G. S. (2008). Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nature Reviews Drug Discovery, 7, 489-503.
53. Gachet, S. M., Rhyn, P., Bosch, O., Quednow, B., & Gertsch, J. (2014). A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma. Journal of Chromatography B, 976-977, 6-18.
54. Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society, 86, 1646-1647.
55. Gerdeman, G. L., Ronesi, J., & Lovinger, D. M. (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience, 5, 446-451.
56. Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M., & Deutsch, D. G. (2003). Evidence against the presence of an anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America, 100, 4269-4274.
57. Glaser, S. T., Kaczocha, M., & Deutsch, D. G. (2005). Anandamide transport: A critical review. Life Sciences, 77, 1584-1604.
58. Goodfellow, C. E., & Glass, M. (2009). Anandamide receptor signal transduction. Vitamins and Hormones, 81, 79-110.
59. Goparaju, S. K., Ueda, N., Taniguchi, K., & Yamamoto, S. (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochemical Pharmacology, 57, 417-423.
60. Guindon, J., & Hohmann, A. (2009). The endocannabinoid system and pain. CNS & Neurological Disorders Drug Targets, 8, 403-421.
61. Gulyas, A., Cravatt, B. F., Bracey, M. H., Dinh, T. P., Piomelli, D., Boscia, F., et al. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. The European Journal of Neuroscience, 20, 441-458.
62. Haenisch, B., & Boenisch, H. (2011). Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacology and Therapeutics, 129, 352-368.
63. Hajdu, Z., Nicolussi, S., & Rau, M. (2014). Identification of endocannabinoid systemmodulating N-alkylamides from Heliopsis helianthoides var. scabra and Lepidium meyenii. Journal of Natural Products, 77(7), 1663-1669.
64. Hajos, N., Kathuria, S., Dinh, T., Piomelli, D., & Freud, T. (2004). Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: Effects of low temperature and the transport inhibitor AM404. European Journal of Neuroscience, 19, 2991-2996.
65. Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., et al. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 3662-3665.
66. Hermann, A., Kaczocha, M., & Deutsch, D. G. (2006). 2-Arachidonoylglycerol (2-AG) membrane transport: History and outlook. The AAPS Journal, 8, E409-E412.
67. Hillard, C. J., Edgemond, W. S., Jarrahian, A., & Campbell, W. B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry, 69, 631-638.
68. Hillard, C. J., & Jarrahian, A. (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chemistry and Physics of Lipids, 108, 123-134.
69. Hillard, C. J., & Jarrahian, A. (2003). Cellular accumulation of anandamide: Consensus and controversy. British Journal of Pharmacology, 140, 802-808.
70. Hillard, C. J., & Jarrahian, A. (2005). Accumulation of anandamide: Evidence for cellular diversity. Neuropharmacology, 48, 1072-1078.
71. Hillard, C. J., Shi, L., Tuniki, V. R., Falck, J. R., & Campbell, W. B. (2007). Studies of anandamide accumulation inhibitors in cerebellar granule neurons: Comparison to inhibition of fatty acid amide hydrolase. Journal of Molecular Neuroscience, 33, 18-24.
72. Hofmann, N. A., Barth, S., Waldeck-Weiermair, M., Klec, C., Strunk, D., Malli, R., et al. (2014). TRPV1 mediates cellular uptake of anandamide and thus promotes endothelial cell proliferation and network-formation. Biology Open, 3, 1164-1172.
73. Högestätt, E. D., Jönsson, B. A. G., Ermund, A., Andersson, D. A., Björk, H., Alexander, J. P., et al. (2005). Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. The Journal of Biological Chemistry, 280, 31405-31412.
74. Houy, S., Croisé, P., Gubar, O., Chasserot-Golaz, S., Tryoen-Tóth, P., Bailly, Y., et al. (2013). Exocytosis and endocytosis in neuroendocrine cells: Inseparable membranes!. Frontiers in Endocrinology, 4, 135.
75. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54, 161-202.
76. Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 99, 8400-8405.
77. Jarrahian, A., Manna, S., Edgemond, W., Campbell, W., & Hillard, C. (2000). Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter. Journal of Neurochemistry, 74, 2597-2606.
78. Kaczocha, M., Glaser, S. T., & Deutsch, D. G. (2009). Identification of intracellular carriers for the endocannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America, 106, 6375-6380.
79. Kaczocha, M., Hermann, A., Glaser, S. T., Bojesen, I. N., & Deutsch, D. G. (2006). Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. The Journal of Biological Chemistry, 281, 9066-9075.
80. Kaczocha, M., Rebecchi, M. J., Ralph, B. P., Teng, Y.-H. G., Berger, W. T., Galbavy, W., et al. (2014). Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One, 9, e94200.
81. Kaczocha, M., Vivieca, S., Sun, J., Glaser, S. T., & Deutsch, D. G. (2012). Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. The Journal of Biological Chemistry, 287, 3415-3424.
82. Khanolkar, A. D., Abadji, V., Lin, S., Hill, W. A., Taha, G., Abouzid, K., et al. (1996). Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. Journal of Medicinal Chemistry, 39, 4515-4519.
83. Kleyer, J., Nicolussi, S., Taylor, P., Simonelli, D., Furger, E., Anderle, P., et al. (2012). Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochemical Pharmacology, 83, 1393-1412.
84. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., et al. (1998). 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: Identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through Ca2+-dependent and-independent mechanisms. FEBS Letters, 429, 152-156.
85. Leung, K., Elmes, M. W., Glaser, S. T., Deutsch, D. G., & Kaczocha, M. (2013). Role of FAAH-like anandamide transporter in anandamide inactivation. PLoS One, 8, e79355.
86. Liedhegner, E. S., Vogt, C. D., Sem, D. S., Cunningham, C. W., & Hillard, C. J. (2014). Sterol carrier protein-2: Binding protein for endocannabinoids. Molecular Neurobiology, 50, 149-158.
87. Ligresti, A., Morera, E., Van Der Stelt, M., Monory, K., Lutz, B., Ortar, G., et al. (2004). Further evidence for the existence of a specific process for the membrane transport of anandamide. The Biochemical Journal, 380, 265-272.
88. Ligresti, A., Petrosino, S., & Di Marzo, V. (2009). From endocannabinoid profiling to "endocannabinoid therapeutics" Current Opinion in Chemical Biology, 13, 321-331.
89. Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., et al. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology, 5, 37-44.
90. López-Rodríguez, M. L., Viso, A., Ortega-Gutiérrez, S., Fowler, C. J., Tiger, G., De Lago, E., et al. (2003a). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase. Journal of Medicinal Chemistry, 46, 1512-1522.
91. López-Rodríguez, M. L., Viso, A., Ortega-Gutiérrez, S., Fowler, C. J., Tiger, G., De Lago, E., et al. (2003b). Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. European Journal of Medicinal Chemistry, 38, 403-412.
92. López-Rodríguez, M. L., Viso, A., Ortega-Gutiérrez, S., Lastres-Becker, I., González, S., Fernández-Ruiz, J., et al. (2001). Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. Journal of Medicinal Chemistry, 44, 4505-4508.
93. Lutz, B. (2009). Endocannabinoid signals in the control of emotion. Current Opinion in Pharmacology, 9, 46-52.
94. Maccarrone, M., Bari, M., Battista, N., & Finazzi-Agrò , A. (2002). Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood, 100, 4040-4048.
95. Maccarrone, M., Bari, M., Lorenzon, T., Bisogno, T., Di Marzo, V., & Finazzi-Agrò, A. (2000). Anandamide uptake by human endothelial cells and its regulation by nitric oxide. The Journal of Biological Chemistry, 275, 13484-13492.
96. Maccarrone, M., Dainese, E., & Oddi, S. (2010). Intracellular trafficking of anandamide: New concepts for signaling. Trends in Biochemical Sciences, 35, 601-608.
97. Maccarrone, M., Fiorucci, L., Erba, F., Bari, M., Finazzi-Agrò , A., & Ascoli, F. (2000). Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Letters, 468, 176-180.
98. Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G., Vliegenthart, J. F., & Agrò, A. (1998). Anandamide hydrolysis by human cells in culture and brain. The Journal of Biological Chemistry, 273, 32332-32339.
99. Marazzi, J., Kleyer, J., Paredes, J. M., & Gertsch, J. (2011). Endocannabinoid content in fetal bovine sera-Unexpected effects on mononuclear cells and osteoclastogenesis. Journal of Immunological Methods, 373, 219-228.
100. Marinelli, S., Di Marzo, V., Florenzano, F., Fezza, F., Viscomi, M. T., van der Stelt, M., et al. (2007). N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology, 32, 298-308.
101. Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., et al. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nature Neuroscience, 13, 951-957.
102. Masson, J., Sagné, C., Hamon, M., & El Mestikawy, S. (1999). Neurotransmitter transporters in the central nervous system. Pharmacological Reviews, 51, 439-464.
103. Matsuda, L., Lolait, S., Brownstein, M., Young, A. C., & Bonner, T. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
104. McFarland, M., Bardell, T., & Yates, M. (2008). RNA interference-mediated knockdown of dynamin 2 reduces endocannabinoid uptake into neuronal dCAD cells. Molecular Pharmacology, 74, 101-108.
105. McFarland, M. J., & Barker, E. L. (2004). Anandamide transport. Pharmacology & Therapeutics, 104, 117-135.
106. McFarland, M. J., Porter, A. C., Rakhshan, F. R., Rawat, D. S., Gibbs, R. A., & Barker, E. L. (2004). A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. The Journal of Biological Chemistry, 279, 41991-41997.
107. Mechoulam, R., & Deutsch, D. G. (2005). Toward an anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America, 102, 17541-17542.
108. Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21-47.
109. Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H., Julius, D., Bifulco, M., et al. (1999). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): Vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochemical and Biophysical Research Communications, 262, 275-284.
110. Millns, P. J., Chimenti, M., Ali, N., Ryland, E., de Lago, E., Fernandez-Ruiz, J., et al. (2006). Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB receptors. European Journal of Neuroscience, 24, 3489-3495.
111. Moore, S. A., Nomikos, G. G., Dickason-Chesterfield, A. K., Schober, D. A., Schaus, J. M., Ying, B., et al. (2005). Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proceedings of the National Academy of Sciences of the United States of America, 102, 17852-17857.
112. Mor, M., Rivara, S., Lodola, A., Plazzi, P. V., Tarzia, G., Duranti, A., et al. (2004). Cyclohexylcarbamic acid 3'-or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. Journal of Medicinal Chemistry, 47, 4998-5008.
113. Muccioli, G. G. (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today, 15, 474-483.
114. Murataeva, N., Straiker, A., & Mackie, K. (2013). Parsing the players: 2-AG synthesis and degradation in the CNS. British Journal of Pharmacology, 171, 1379-1391.
115. Nicolussi, S. (2014). Identification and characterization of potent and selective inhibitors of endocannabinoid uptake (pp. 1-173). Doctoral dissertation. Available from GCB Graduate School, University of Bern, Switzerland.
116. Nicolussi, S., Chicca, A., Rau, M., Rihs, S., Soeberdt, M., Abels, C., et al. (2014). Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: From ultrapotent to hyperpotent. Biochemical Pharmacology, 92, 669-689.
117. Nicolussi, S., Viveros-Paredes, J. M., Gachet, M. S., Rau, M., Flores-Soto, M. E., Blunder, M., et al. (2014). Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 80C, 52-65.
118. Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science, 334, 809-813.
119. O'Brien, L. D., Limebeer, C. L., Rock, E. M., Bottegoni, G., Piomelli, D., & Parker, L. A. (2013). Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus). British Journal of Pharmacology, 170, 1130-1136.
120. Oddi, S., Fezza, F., Catanzaro, G., De Simone, C., Pucci, M., Piomelli, D., et al. (2010). Pitfalls and solutions in assaying anandamide transport in cells. Journal of Lipid Research, 51, 2435-2444.
121. Oddi, S., Fezza, F., Pasquariello, N., D'Agostino, A., Catanzaro, G., De Simone, C., et al. (2009). Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chemistry & Biology, 16, 624-632.
122. Oddi, S., Fezza, F., Pasquariello, N., De Simone, C., Rapino, C., Dainese, E., et al. (2008). Evidence for the intracellular accumulation of anandamide in adiposomes. Cellular and Molecular Life Sciences, 65, 840-850.
123. Ortar, G., Cascio, M. G., Moriello, A. S., Camalli, M., Morera, E., Nalli, M., et al. (2008). Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. European Journal of Medicinal Chemistry, 43, 62-72.
124. Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E., & Di Marzo, V. (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochemical Pharmacology, 65, 1473-1481.
125. Ortega-Gutiérrez, S., Hawkins, E. G., Viso, A., López-Rodríguez, M. L., & Cravatt, B. F. (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: Evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry, 43, 8184-8190.
126. Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease-Successes and failures. The FEBS Journal, 280, 1918-1943.
127. Pacher, P., & Mechoulam, R. (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progress in Lipid Research, 50, 193-211.
128. Pertwee, R. G. (2014). Elevating endocannabinoid levels: Pharmacological strategies and potential therapeutic applications. The Proceedings of the Nutrition Society, 73, 96-105.
129. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacological Reviews, 62, 588-631.
130. Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4, 873-884.
131. Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S. Y., Goutopoulos, A., Xie, X. Q., et al. (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America, 96, 5802-5807.
132. Porter, A. C., Sauer, J., Knierman, M. D., Becker, G.W., Berna, M. J., Bao, J., et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. The Journal of Pharmacology and Experimental Therapeutics, 301, 1020-1024.
133. Price, T. J., Patwardhan, A. M., Flores, C. M., & Hargreaves, K. M. (2005). A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons. Neuropharmacology, 49, 25-39.
134. Rakhshan, F., Day, T., Blakely, R., & Barker, E. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. The Journal of Pharmacology and Experimental Therapeutics, 292, 960-967.
135. Rimmerman, N., Bradshaw, H. B., Kozela, E., Levy, R., Juknat, A., & Vogel, Z. (2012). Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1. British Journal of Pharmacology, 165, 2436-2449.
136. Rimmerman, N., Hughes, H. V., Bradshaw, H. B., Pazos, M. X., Mackie, K., Prieto, A. L., et al. (2008). Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. British Journal of Pharmacology, 153, 380-389.
137. Ronesi, J., Gerdeman, G. L., & Lovinger, D. M. (2004). Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 24, 1673-1679.
138. Ross, R. A. (2003). Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology, 140, 790-801.
139. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152, 1092-1101.
140. Saario, S. M., Salo, O. M. H., Nevalainen, T., Poso, A., Laitinen, J. T., Järvinen, T., et al. (2005). Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chemistry & Biology, 12, 649-656.
141. Sanson, B., Wang, T., Sun, J., Wang, L., Kaczocha, M., Ojima, I., et al. (2014). Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. Acta Crystallographica Section D: Biological Crystallography, 70, 290-298.
142. Savinainen, J. R., Saario, S. M., & Laitinen, J. T. (2011). The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiologica (Oxford, England), 204, 267-276.
143. Schreiber, D., Harlfinger, S., Nolden, B. M., Gerth, C. W., Jaehde, U., Schömig, E., et al. (2007). Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Analytical Biochemistry, 361, 162-168.
144. Sigel, E., Baur, R., Racz, I., Marazzi, J., Smart, T. G., Zimmer, A., et al. (2011). The major central endocannabinoid directly acts at GABAA receptors. Proceedings of the National Academy of Sciences of the United States of America, 108, 18150-18155.
145. Skaper, S. D., & Di Marzo, V. (2012). Endocannabinoids in nervous system health and disease: The big picture in a nutshell. Philosophical Transactions of the Royal Society B, 367, 3193-3200.
146. Stella, N., Schweitzer, P., & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
147. Sulsky, R., Magnin, D. R., Huang, Y., Simpkins, L., Taunk, P., Patel, M., et al. (2007). Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorganic & Medicinal Chemistry Letters, 17, 3511-3515.
148. Sun, Y., Alexander, S. P., Kendall, D. A., & Bennett, A. J. (2008). Involvement of fatty acid binding proteins in the transport of endocannabinoids to peroxisome proliferator activated receptors. In 18th annual symposium of the international cannabinoid research society (ICRS), 1, 17, (Program and Abstracts).
149. Vandevoorde, S., & Fowler, C. J. (2005). Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: Evidence that VDM11 acts as an FAAH substrate. British Journal of Pharmacology, 145, 885-893.
150. Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., & Nilius, B. (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 424, 434-438.
151. Yates, M., & Barker, E. L. (2009a). Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Molecular Pharmacology, 76, 11-17.
152. Yates, M. L., & Barker, E. L. (2009b). Organized trafficking of anandamide and related lipids. Vitamins and Hormones, 81, 25-53.
153. Yu, S., Levi, L., Casadesus, G., Kunos, G., & Noy, N. (2014). Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. Journal of Biological Chemistry, 289, 12748-12758.
154. Zygmunt, P. M., Chuang, H., Movahed, P., Julius, D., & Högestätt, E. D. (2000). The anandamide transport inhibitor AM404 activates vanilloid receptors. European Journal of Pharmacology, 396, 39-42.